MYIA
FOLD

Mount Yale Investment Advisors’s Amicus Therapeutics FOLD Stock Holding History

Mount Yale Investment Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.31M Sell
367,179
-378
-0.1% -$5.42K 0.12% 176
2025
Q4 		$5.23M Sell
367,557
-8,163
-2% -$80.2K 0.25% 81
2025
Q3 		$2.96M Buy
+375,720
New +$2.67M 0.21% 112
2024
Q3 		– Sell
-11,431
Closed -$113K – 568
2024
Q2 		$113K Sell
11,431
-17
-0.1% -$175 0.01% 527
2024
Q1 		$135K Buy
11,448
+304
+3% +$3.89K 0.01% 523
2023
Q4 		$158K Buy
11,144
+61
+0.6% +$693 0.02% 480
2023
Q3 		$135K Buy
+11,083
New +$143K 0.01% 486

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Mount Yale Investment Advisors's FOLD Position: Q1 2026 in Review

Mount Yale Investment Advisors reduced its Amicus Therapeutics (FOLD) stake by 0.1% in Q1 2026, selling an estimated $5.42K and leaving 367,179 shares worth $5.31M. The position accounts for 0.12% of the portfolio, ranked #176.

Mount Yale Investment Advisors first reported a position in FOLD in Q3 2023 and has held it in 7 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Mount Yale Investment Advisors held 367,179 shares of Amicus Therapeutics worth $5.31M as of Q1 2026.
  • Mount Yale Investment Advisors sold 378 Amicus Therapeutics shares in Q1 2026, an estimated $5.42K.
  • Amicus Therapeutics made up 0.12% of Mount Yale Investment Advisors's portfolio in Q1 2026, its #176 holding.
  • Mount Yale Investment Advisors first reported a position in Amicus Therapeutics in Q3 2023 and has held it in 7 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.